Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Robert Clark to move to Novo Nordisk

Will join firm’s US operations as vice president of regulatory affairs

Novo Nordisk has appointed Robert Clark as vice president of regulatory affairs in a role that will see him lead the Danish pharma company's US regulatory team.

He will also be tasked with maintaining “relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the US Food and Drug Administration's (FDA) review and approval process”, Novo said.

Clark will join the company on May 14 from Pfizer, where he was US regulatory strategy head, leading or supporting approvals of new cardiovascular, endocrine, women's health and anti-infective medicines.

"Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it's that know-how we require for an increasingly complex pharmaceutical marketplace," said Anne Philips, corporate vice president of clinical development, medical and regulatory affairs at Novo Nordisk.

"Novo Nordisk has one of the most promising diabetes pipelines in the industry, and having a respected leader known to regulatory authorities will help us achieve our ongoing mission to bring new therapies to patients."

9th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...